Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-296-3 | CAS number: 56-89-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
L-Cystine was found to be practically non-toxic after oral and dermal application.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions: article in Japanese, has been translated into English
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Principles of method if other than guideline:
- Two dose groups were tested and the findings recorded.
The oral LD50 could not be detemined. - GLP compliance:
- not specified
- Test type:
- other: two dose groups were tested
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 5 weeks
- Fasting period before study: 16h
- Housing: seperate cages
- Diet: CA-1 pellets
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 55 +/- 5 - Route of administration:
- oral: gavage
- Vehicle:
- other: 5% gum arabic aqueous solution
- Details on oral exposure:
- Cystine was suspended in 5% gum arabic aqueous solution, which weas adminstered at a dose of 5 mL/100g of bw. The administratinon dose was
10000 mg/kg or 25000 mg/kg of bw, which is the maximum allowable administration quantity, and the administration was given orally,
forcibly and using a feeding tube. - Doses:
- 5 mL/100g of bw
The administratino dose was 10000 mg/kg or 25000 mg/kg of bw. - No. of animals per sex per dose:
- 10/sex/group
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 7 days
- Necropsy of survivors performed: yes
- Other examinations performed: symptom and body weight changes - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 25 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- After 48 h one rat died but the remaining rats returned to normal by 72 hours.
- Clinical signs:
- other: A decrease in spontaneous exercise was seen in two or three of the females 24 to 48 hours after administration, a drop in body temperature and dirtying around the lower abdomen were observed.
- Gross pathology:
- The results of the autopsy showed punctatebleeding on the stomach fundus and hematuria in the bladder, though there were no particular abnormal findings in the living specimens.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: Japan
- Conclusions:
- One female specimen died in the cystine 25000 mg/kg group.
The LD50 value was at least 25000 mg/kg. - Executive summary:
One female specimen died in the cystine 25000 mg/kg group.
The LD50 value was at least 25000 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 25 000 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: OECD Guideline study performed under GLP conditions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- dressing: gauze and non-irritating tape
- Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 male and 5 female
- Control animals:
- not required
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- no mortality
- Clinical signs:
- other: No signs of toxicity. Scratches were observed in one male animal. These signs of irritation were not reversible within the observation period (14 days).
- Gross pathology:
- No special findings
- Other findings:
- None
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: OECD GHS
- Conclusions:
- Under the condition of the present study, single dermal application of the test item L-Cystine to rats at a dose of 2000 mg/kg body weight was
associated with neither mortality nor signs of toxicity but slight signs of irritation. - Executive summary:
The dermal LD50 was determined to be > 2000 mg L-Cystine / kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
L-Cystine was tested in an acute oral toxicity study in Wistar rats (10/sex/dose). The administratinon dose was 10000 mg/kg and 25000 mg/kg of bw, administered via a feeding tube. One female specimen died in the cystine 25000 mg/kg group. No change in the animals' symptoms were found during the seven days following administration; no particular findings were observed in the autopsies.
The LD50 value was at least 25000 mg/kg.
Under the condition of a OECD 402 guideline study, single dermal application (24 h, semiocclusive) of the test item L-Cystine to rats (5 male and 5 female animals) at a dose of 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity but slight signs of irritation (scratches were observed in one male animal). These signs of irritation were not reversible within the observation period (14 days).
The dermal LD50 was determined to be > 2000 mg L-Cystine / kg body weight.
Justification for selection of acute toxicity – oral endpoint
Comparable to guideline study with acceptable restrictions: article in Japanese, has been translated into English.
Justification for selection of acute toxicity – dermal endpoint
Guideline study according to OECD 402.
Justification for classification or non-classification
The oral LD50 in an acute rat study was found to be > 25000 mg/kg and results in non-classification for the endpoint.
The dermal LD50 in an scute rat study was found to be > 2000 mg/kg and results in non-classification for the endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.